Clinical efficacy and safety of fondaparinux: an emphasis on results in the elderly

Author: Turpie, AGG

Source: Aging Health, 1 October 2006, vol. 2, no. 5, pp. 731-743(13)


Buy & download fulltext article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.


Fondaparinux is a synthetic selective factor Xa inhibitor. Owing to its favorable pharmacological profile, fondaparinux is subcutaneously administered once daily without laboratory monitoring of its anticoagulant activity (and also of platelet count in Europe) in all its indications. Its efficacy and safety have been investigated in numerous areas, including the prevention of venous thromboembolism in surgical and medically-ill patients, treatment of deep-vein thrombosis and pulmonary embolism, and treatment of patients with non-ST- or ST-elevation acute coronary syndromes. This review presents the results obtained in these different clinical settings, with particular attention to the results obtained in the elderly, a population largely involved in the studies.

Keywords: acute coronary syndromes; anticoagulant; antithrombotic; deep-vein thrombosis; factor Xa; fondaparinux; heparin; low-molecular-weight heparin; pulmonary embolism; venous thromboembolism

Document Type: Drug Evaluation


Affiliations: Hamilton Health Sciences General Division, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada., Email:

Publication date: October 1, 2006

Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page